172 related articles for article (PubMed ID: 35621918)
1. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers.
Niger M; Nichetti F; Casadei-Gardini A; Morano F; Pircher C; Tamborini E; Perrone F; Canale M; Lipka DB; Vingiani A; Agnelli L; Dobberkau A; Hüllein J; Korell F; Heilig CE; Pusceddu S; Corti F; Droz M; Ulivi P; Prisciandaro M; Antista M; Bini M; Cattaneo L; Milione M; Glimm H; Köhler BC; Pruneri G; Hübschmann D; Fröhling S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
Mol Oncol; 2022 Jul; 16(14):2733-2746. PubMed ID: 35621918
[TBL] [Abstract][Full Text] [Related]
2. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
Schwartz S; Szeto C; Tian Y; Cecchi F; Corallo S; Calegari MA; Di Bartolomeo M; Morano F; Raimondi A; Fucà G; Martinetti A; De Pascalis I; Martini M; Belfiore A; Milione M; Orlandi A; Barault L; Barone C; de Braud F; Di Nicolantonio F; Benz S; Hembrough T; Pietrantonio F
Eur J Cancer; 2019 Jan; 107():164-174. PubMed ID: 30579113
[TBL] [Abstract][Full Text] [Related]
3. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
[TBL] [Abstract][Full Text] [Related]
5. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
Richard S; Tachon G; Milin S; Wager M; Karayan-Tapon L
Cancer Med; 2020 Sep; 9(17):6344-6353. PubMed ID: 32666673
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
7. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
Chen J; Li Z; Chen J; Du Y; Song W; Xuan Z; Zhao L; Song G; Song P; Zheng S
Clin Transl Oncol; 2020 Mar; 22(3):392-400. PubMed ID: 31264147
[TBL] [Abstract][Full Text] [Related]
9. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Wu PF; Kuo KT; Kuo LT; Lin YT; Lee WC; Lu YS; Yang CH; Wu RM; Tu YK; Tasi JC; Tseng HM; Tseng SH; Cheng AL; Lin CH
Lung Cancer; 2010 Jun; 68(3):484-90. PubMed ID: 19740564
[TBL] [Abstract][Full Text] [Related]
10. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
Kakkar A; Kumar A; Jha P; Goyal N; Mallick S; Sharma MC; Suri A; Singh M; Kale SS; Julka PK; Sarkar C; Suri V
Neuropathology; 2014 Aug; 34(4):333-42. PubMed ID: 24521400
[TBL] [Abstract][Full Text] [Related]
11. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Amatu A; Barault L; Moutinho C; Cassingena A; Bencardino K; Ghezzi S; Palmeri L; Bonazzina E; Tosi F; Ricotta R; Cipani T; Crivori P; Gatto R; Chirico G; Marrapese G; Truini M; Bardelli A; Esteller M; Di Nicolantonio F; Sartore-Bianchi A; Siena S
Ann Oncol; 2016 Jun; 27(6):1062-1067. PubMed ID: 26916096
[TBL] [Abstract][Full Text] [Related]
12. MGMT Status as a Clinical Biomarker in Glioblastoma.
Butler M; Pongor L; Su YT; Xi L; Raffeld M; Quezado M; Trepel J; Aldape K; Pommier Y; Wu J
Trends Cancer; 2020 May; 6(5):380-391. PubMed ID: 32348734
[TBL] [Abstract][Full Text] [Related]
13. Impact of catechol-O-methyltransferase gene variants on methylation status of P16 and MGMT genes and their downregulation in colorectal cancer.
Wani HA; Majid S; Bhat AA; Amin S; Farooq R; Bhat SA; Naikoo NA; Beigh MA; Kadla SA
Eur J Cancer Prev; 2019 Mar; 28(2):68-75. PubMed ID: 30379684
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and Predictive Value of O
Zhang J; Zhu Y; Wang Y; Fu Q; Xie H; Liu Z; Fu H; Cao Y; Xu J; Dai B
Ann Surg Oncol; 2018 Jan; 25(1):342-348. PubMed ID: 29116491
[TBL] [Abstract][Full Text] [Related]
15. Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
Pandith AA; Qasim I; Zahoor W; Shah P; Bhat AR; Sanadhya D; Shah ZA; Naikoo NA
Sci Rep; 2018 Apr; 8(1):6704. PubMed ID: 29712977
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Fiano V; Trevisan M; Trevisan E; Senetta R; Castiglione A; Sacerdote C; Gillio-Tos A; De Marco L; Grasso C; Magistrello M; Tondat F; Rudà R; Cassoni P; Soffietti R; Merletti F
J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517
[TBL] [Abstract][Full Text] [Related]
18. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.
Shima K; Morikawa T; Baba Y; Nosho K; Suzuki M; Yamauchi M; Hayashi M; Giovannucci E; Fuchs CS; Ogino S
Cancer Causes Control; 2011 Feb; 22(2):301-9. PubMed ID: 21140203
[TBL] [Abstract][Full Text] [Related]
19. Improved local control in p16 negative oropharyngeal cancers with hypermethylated MGMT.
Jensen GL; Axelrud G; Fink D; Hammonds K; Walker K; Volz M; Gowan A; Rao A; Deb N; Jhavar SG
Radiother Oncol; 2021 Apr; 157():234-240. PubMed ID: 33577867
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
